The basic science of sepsis

Surgery

Volumn 27, Issue 11, 2009, Pages 465-469

  Treacher, David F ^a,b   Alun Brown, K ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

cytokines; neutrophils; organ failure; sepsis; systemic inflammation

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; DROTRECOGIN; INOTROPIC AGENT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THROMBOCYTE ACTIVATING FACTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASOCONSTRICTOR AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIAL DYSFUNCTION; FIBRIN DEPOSITION; GRANULOCYTOSIS; HEART EDEMA; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INTENSIVE CARE; MULTIPLE ORGAN FAILURE; MYOCARDIAL HIBERNATION; NEISSERIA MENINGITIDIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEPSIS; SEPTIC SHOCK; THROMBOCYTOPENIA;

EID: 72049116053     PISSN: 02639319     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpsur.2009.09.001     Document Type: Review

References (25)

1. Levy M.M., Fink M.P., Marshall J.C., et al. 2001 SCCM/EISCM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 (2003) 521-524
2. Rivers E.P., and Ahrens T. Improving outcomes for severe sepsis and septic shock: tools for early identification of at-risk patients and treatment protocol implementation. Crit Care Clin 24 (2008) 1-47
3. Vincent J.-L., and Abraham E. The last 100 years of sepsis. Am J Respir Crit Care Med 173 (2006) 256-263
4. Cohen J. The immunopathogenesis of sepsis. Nature 420 (2004) 885-891
5. Vilcek J., and Feldman M. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci 25 (2004) 201-209
6. Gogos C.A., Drosou E., Basssaris H.P., and Skoutelis A. J Infect Dis 181 (2000) 176-180
7. Weighardt H., and Holzmann B. Role of toll-like receptor responses for sepsis pathogenesis. Immunobiology 212 (2007) 715-722
8. Cavaillon J.-M. Pathophysiological role of pro- and anti-inflammatory cytokines in sepsis. Sepsis 2 (1998) 127-140
9. Marshall J.C. Sepsis: current status, future prospects. Curr Opin Crit Care 10 (2004) 250-264
10. Ward N.S., Casserley B., and Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med 29 (2008) 617-625
11. Hotchkiss R.S., and Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 348 (2003) 138-150
12. Aldridge A.J. Role of the neutrophil in septic shock and the adult respiratory distress syndrome. Eur J Surg 168 (2002) 204-214
13. Puneet P., Moochala S., and Bhatia M. Chemokines in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 288 (2005) 3-15
14. Sato T., Shinzawa H., Abe Y., et al. Inhibition of Corynebacterium parvum-primed and lipopolysaccharide-induced hepatic necrosis in rats by selective depletion of neutrophils using monoclonal antibody. J Leukoc Biol 53 (1993) 144-150
15. Treacher D.F., Sabbato M., Brown K.A., et al. The effects of leucodepletion in patients who develop the systemic inflammatory response syndrome following cardiopulmonary bypass. Perfusion 16 (2001) S67-S74
16. Brown K.A., Brain S.D., Pearson J.D., et al. Neutrophils in development of multiple organ failure in sepsis. Lancet 368 (2006) 157-169
17. Levi M. The coagulant response in sepsis. Clin Chest Med 29 (2008) 627-642
18. Weiler H., and Ruf W. Activated protein C in sepsis: the promise of non-anticoagulant activated protein C. Curr Opin Hematol 15 (2008) 487-493
19. Lin S.M., Wang Y.M., Lin H.C., et al. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome and morality in patients with sepsis. Crit Care Med 36 (2008) 683-689
20. Cauwels A. Nitric oxide in shock. Kidney Int 72 (2007) 57-65
21. Fernandes Jr. C.J., Akamine N., and Knobel E. Myocardial depression in sepsis. Shock 30 (2008) 14-17
22. Singer M., De Santis V., Vitale D., et al. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 364 (2004) 545-548
23. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
24. Tolt L.J., Swystun L.L., Pepler L., et al. Protective effects of activated protein C in sepsis. Thromb Haemost 100 (2008) 589-592
25. Lopez A., Lorente J.A., Steingrub J., et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32 (2004) 21-30